Physician profile
Soohan Mansuri
NPI 1194179887
$2,141.00
in general payments reported to CMS, 2019-2025
23 companies · $117 in 2025
The $117 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $230 · 2021: $153 · 2022: $226 · 2023: $568 · 2024: $847 · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,532.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,531.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $347.76 | 2019-2025 | |
| Novo Nordisk INC | $323.94 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $218.25 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $171.23 | 2021-2024 | |
| Lilly USA, LLC | $165.77 | 2023-2024 | Jardiance, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $133.59 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $128.60 | 2021-2024 | Repatha, Otezla |
| E.R. Squibb & Sons, L.L.C. | $124.30 | 2019-2023 | Eliquis |
| Covidien LP | $93.01 | 2019 | |
| Daiichi Sankyo INC. | $91.88 | 2022-2024 | Injectafer |
| Ucb, INC. | $68.74 | 2023-2024 | Nayzilam, Briviact |
| Exact Sciences Corporation | $54.38 | 2024-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $45.02 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.15 | 2024 | Jardiance, Tradjenta |
| Sunovion Pharmaceuticals INC. | $21.43 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $20.93 | 2023 | Freestyle Libre 2 |
| Aimmune Therapeutics, INC. | $19.79 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.91 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.00 | 2023 | Xifaxan |
| Shield Therapeutics INC | $15.87 | 2023 | Accrufer |
| Teva Pharmaceuticals USA, INC. | $14.67 | 2023 | Austedo Xr |
| Phathom Pharmaceuticals, INC. | $13.48 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $11.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Soohan Mansuri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.